Literature DB >> 11755457

Assessing Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory: scoring and clinical implications.

Myron F Weiner1, Rochelle E Tractenberg, Shelia Jin, Anthony Gamst, Ronald G Thomas, Elisabeth Koss, Leon J Thal.   

Abstract

We explored the applicability of the standard scoring of the Cohen-Mansfield Agitation Inventory (CMAI), a widely used nursing-home derived instrument, to community-dwelling persons with Alzheimer's disease (AD). Item responses to the CMAI were gathered from participants in two large clinical studies, one of which specifically included patients with behavioral disturbances. Confirmatory factor analysis in these two groups of well-characterized AD patients suggested that conventional CMAI subscoring did not adequately describe the responses of these two groups. Exploratory factor analysis indicated that the four CMAI subscores, based on a verbal-physical and aggressive-non-aggressive conceptualization of behavioral disturbance, did not fit community dwelling persons with AD. Based on cross-sectional and longitudinal analyses, there was suggestive evidence for three behavioral clusters, but these clusters did not achieve statistical significance Overall, the CMAI seemed best suited to describe the overall level rather than the specific subtypes of behavioral dyscontrol in community-dwelling persons with AD.

Entities:  

Mesh:

Year:  2002        PMID: 11755457     DOI: 10.1016/s0022-3956(01)00047-4

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  6 in total

Review 1.  Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia: a systematic review.

Authors:  Jodie Belinda Hillen; Natalie Soulsby; Chris Alderman; Gillian E Caughey
Journal:  Ther Adv Drug Saf       Date:  2019-05-15

2.  The DemWG study: reducing the risk of hospitalisation through a complex intervention for people with dementia and mild cognitive impairment (MCI) in German shared-housing arrangements: study protocol of a prospective, mixed-methods, multicentre, cluster-randomised controlled trial.

Authors:  André Kratzer; Jennifer Scheel; Karin Wolf-Ostermann; Annika Schmidt; Katrin Ratz; Carolin Donath; Elmar Graessel
Journal:  BMJ Open       Date:  2020-12-02       Impact factor: 2.692

3.  Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial.

Authors:  Vered Hermush; Liora Ore; Noa Stern; Nisim Mizrahi; Malki Fried; Marina Krivoshey; Ella Staghon; Violeta E Lederman; Lihi Bar-Lev Schleider
Journal:  Front Med (Lausanne)       Date:  2022-09-06

4.  Specific agitation behaviours in dementia differentially contribute to aspects of caregiver burden.

Authors:  Karlee S Patrick; John Gunstad; John T Martin; Kimberly R Chapman; Jennifer Drost; Mary Beth Spitznagel
Journal:  Psychogeriatrics       Date:  2022-07-19       Impact factor: 2.295

Review 5.  Management of psychosis in patients with Alzheimer's disease: focus on aripiprazole.

Authors:  Subramanian Madhusoodanan; Payal Shah
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

6.  Neuropsychiatric symptoms in patients with dementia in primary care: a study protocol.

Authors:  Petra Borsje; Roland B Wetzels; Peter L B J Lucassen; Anne-Margriet Pot; Raymond T C M Koopmans
Journal:  BMC Geriatr       Date:  2014-03-17       Impact factor: 3.921

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.